Compare Hubbell (HUBB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hubbell vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hubbell trades at $471.77 (market cap $25.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Hubbell is far larger — about 3.4× Spyre Therapeutics Inc. Common Stock's market cap, and Hubbell pays a 1.19% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HUBB | SYRE | |
|---|---|---|
Market Cap | $25.25B | $7.52B |
Volume | 443,319 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $557.85 | $108.92 |
52-Week Low | $407.36 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.41B | $6.52B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hubbell Incorporated (HUBB) trades at $477.93, up 0.82% with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $4.73 vs. $4.71 expected, Q1 2026: $3.93 vs. $3.87, Q2 2026: $5.52 vs. $5.39) and robust profitability (net margin 14.49%, ROE 24.34%). Recent news highlights grid modernization opportunities and institutional buying interest from Bank of America and BNY Mellon.
Hubbell presents a favorable outlook with analyst consensus price target of $560.50 (17% upside) and strong institutional support. Key risks include integration challenges from recent acquisitions and dependence on utility spending cycles. The Q3 2026 earnings report on October 27 will be crucial for validating growth trajectory amid electrification demand.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
